Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-09-06

Clinical Trial Update: Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis [NA]

View source ↗

Summary

A completed clinical trial studied the effects of natalizumab (Tysabri) on cognition and neurodegeneration in multiple sclerosis, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tysabri (Natalizumab)

Snippet

Sponsor: University of Chicago | Conditions: Multiple Sclerosis | NA | Status: COMPLETED | Results posted: 2017-09-06